Karyopharm Therapeutics Inc (KPTI)

7.38
NASDAQ : Health Care
Prev Close 7.36
Day Low/High 7.13 / 7.50
52 Wk Low/High 4.83 / 22.61
Avg Volume 188.30K
Exchange NASDAQ
Shares Outstanding 35.96M
Market Cap 264.67M
EPS -3.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Purchase Karyopharm Therapeutics At $5, Earn 20.6% Annualized Using Options

Commit To Purchase Karyopharm Therapeutics At $5, Earn 20.6% Annualized Using Options

Investors considering a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $7.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $5 strike, which has a bid at the time of this writing of 60 cents.

Karyopharm Initiates Phase 1 Clinical Trial With KPT-9274

Karyopharm Initiates Phase 1 Clinical Trial With KPT-9274

First-in-class Immunometabolic Modulator, PAK4/NAMPT Inhibitor, to be Evaluated in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Oversold Conditions For Karyopharm Therapeutics (KPTI)

Oversold Conditions For Karyopharm Therapeutics (KPTI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Insider Trading Alert - TRUP, KPTI And FCBC Traded By Insiders

Insider Trading Alert - TRUP, KPTI And FCBC Traded By Insiders

Stocks with insider trader activity include TRUP, KPTI and FCBC

Insider Trading Alert - KPTI, CPIX And LB Traded By Insiders

Insider Trading Alert - KPTI, CPIX And LB Traded By Insiders

Stocks with insider trader activity include KPTI, CPIX and LB

Insider Trading Alert - W, KPTI And GVP Traded By Insiders

Insider Trading Alert - W, KPTI And GVP Traded By Insiders

Stocks with insider trader activity include W, KPTI and GVP

Karyopharm To Present Preliminary STOMP Phase 1B Clinical Data At 2016 European Hematology Association Annual Meeting

Karyopharm To Present Preliminary STOMP Phase 1B Clinical Data At 2016 European Hematology Association Annual Meeting

- Data Describes Early Activity of Selinexor in Combination with Standard of Care Agents for Treatment of Relapsed/Refractory Multiple Myeloma -

Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting

Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting

Single-agent Selinexor in Recurrent Glioblastoma and Selinexor Combination Data in Multiple Myeloma

Karyopharm To Report First Quarter 2016 Financial Results On May 9, 2016

Karyopharm To Report First Quarter 2016 Financial Results On May 9, 2016

Conference Call Scheduled for Monday, May 9, 2016 at 8:30 a.m. ET

Karyopharm Presents Data Demonstrating The Potential Of Nuclear Export Protein Exportin 1 (XPO1) Inhibition In The Treatment Of Traumatic Brain Injury

Karyopharm Presents Data Demonstrating The Potential Of Nuclear Export Protein Exportin 1 (XPO1) Inhibition In The Treatment Of Traumatic Brain Injury

Preclinical data on KPT-350, Karyopharm's Selective Inhibitor of Nuclear Export (SINEā„¢) compound, presented at the 2016 American Academy of Neurology Annual Meeting

Karyopharm Taps TransPerfect As ETMF And Functional TMF Provider

Karyopharm Taps TransPerfect As ETMF And Functional TMF Provider

E-Clinical Solution Enables Karyopharm to Move to a Paperless Global Trial Process

Karyopharm Receives NIAID Grant To Advance Development Of KPT-350 For The Treatment Of Lupus

Karyopharm Receives NIAID Grant To Advance Development Of KPT-350 For The Treatment Of Lupus

KPT-350 Has Demonstrated Efficacy in Animal Models of Neurological, Autoimmune and Inflammatory Conditions

Karyopharm Therapeutics (KPTI) Strong On High Relative Volume Today

Karyopharm Therapeutics (KPTI) Strong On High Relative Volume Today

Trade-Ideas LLC identified Karyopharm Therapeutics (KPTI) as a strong on high relative volume candidate

Karyopharm To Report Fourth Quarter And Full Year 2015 Financial Results On March 14, 2016

Karyopharm To Report Fourth Quarter And Full Year 2015 Financial Results On March 14, 2016

Conference Call Scheduled for Monday, March 14, 2016 at 8:30 a.m. ET

Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology

Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology

Demonstrates Safety and Broad Antitumor Activity in Patients With Advanced Solid Tumors

7 Stocks Under $10 Making Big Breakout Moves

7 Stocks Under $10 Making Big Breakout Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.